Australian Clinical Labs (ASX:ACL) LT-Debt-to-Total-Asset : 0.39 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Australian Clinical Labs's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.39.

Australian Clinical Labs's long-term debt to total assets ratio increased from Dec. 2022 (0.38) to Dec. 2023 (0.39). It may suggest that Australian Clinical Labs is progressively becoming more dependent on debt to grow their business.

Australian Clinical Labs LT-Debt-to-Total-Asset Historical Data

The historical data trend for Australian Clinical Labs's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs LT-Debt-to-Total-Asset Chart

Australian Clinical Labs Annual Data

Trend

Dec20

Jun21

Jun22

Jun23

LT-Debt-to-Total-Asset

0.49

0.47

0.27

0.37

Australian Clinical Labs Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial			0.30	0.27	0.38	0.37	0.39

Australian Clinical Labs LT-Debt-to-Total-Asset Calculation

Australian Clinical Labs's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )	/	Total Assets (A: Jun. 2023 )
	=	215.234	/	578.913
	=	0.37

Australian Clinical Labs's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	225.26	/	583.723
	=	0.39

Australian Clinical Labs (ASX:ACL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Australian Clinical Labs LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Australian Clinical Labs (ASX:ACL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168

Website

https://www.clinicallabs.com.au

Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.

Australian Clinical Labs (ASX:ACL) Headlines

No Headlines